Спайдер незначительно повышается перед открытием торгов на NYSE.
- Европейские индексы на отрицательной территории.
SPY (внутридневной график) боковое движение на премаркете премаркете. Поддержка 178.80, сопротивление 179.80
Премаркет NYSE/NASDAQ:
Повышаются на премаркете:
- In reaction to strong earnings/guidance: STV +9.2%, LZB +8.5% (also increased its quarterly dividend by 50% to $0.06 per share), JCP +5.4%, DE +3.7%, ADT +0.9%, (also enters into accelerated share repurchase agreement to repurchase ~400 mln of common stock).
- M&A news: TEVA +1.6% (Bloomberg discusses merger possibility between Teva and Mylan or VRX, according to reports; upgraded to Positive from Neutral at Susquehanna).
- Select oil/gas related names showing strength: SD +4.5%, RDS.A +0.8%, BP +0.7%.
- Select solar names showing strength: RSOL +10.8%, SPWR +4.3%, JKS +3.4%, TSL +3%, YGE +2.2%, SOL +1.6%.
- Other news: IPCI +21.2% (continued strength), HNR +19.5% (announces revised $400 mln proposal from Pluspetrol for co's interest in Venezuela; termination of negotiations with Vitol), UNIS +17.9% (attributed to reports of deal with Hikma), BMRN +4.9% (confirms FDA Advisory Commitee recommends approval for Vimizim for the treatment of patients with Morquio A syndrome), MDR +4.4% (ticking higher, subsidiaries was awarded project for a customer in the Arabian Gulf. The value is approximately US$ 200 million and will be included in McDermott's fourth quarter 2013 backlog), VEEV +4.3% ( following positive Mad Money mention), OMER +4.1% (announces FDA acceptance of Omidria as proprietary name for OMS302), OTIV +3.3% (Silk & Sons disclosed stake), YHOO +3.1% (increases share buyback authorization by $5 bln), NQ +2.9% (following conference yesterday), NOK +2.6% and ALU +1.3% (still checking), RYAAY +2.3% / ZNH +1.1% (still checking), ARO +2% ( Hirzel Capital disclosed stake), BSX +1.2% (receives FDA clearance and CE Mark approval for Direxion Torqueable Microcatheter), SSYS +1.2% (continued momentum), HLF +0.8% (William P. Stiritz, Chairman of Post Foods (POST), disclosed 6.38% active stake in 13D filing; plans to interact with Company management), CRM +0.7% ( following positive Mad Money mention), CAT +0.6% (following DE results), ZNGA +0.5% (picked up in afternoon trade on reports that the co received favorable patent verdict in Texas case), AMGN +0.5% (announces evolocumab (AMG 145) results from first 52-week study of PCSK9 inhibitor to reduce LDL cholesterol; Amgen tgt to $142 from $138 at Deutsche Bank), FNF +0.4% (Dan Loeb's Third Point Capital reported new stakes (as of 9/30) in FNF (2.1 mln shares) and NLSN (1.0 mln) in an amended 13F filing out last night after the close).
(
Читать дальше )